Saxagliptin in the treatment of diabetes mellitus type 2: focus on the cardiovascular safety
AbstractThe purpose of this article is to describe the efficiency of selective and competitive inhibitor of dipeptidyl peptidase-4 saxagliptin and saxagliptin/metformin extended-release (XR) fixed-dose combination. This article presents results of the assessment of cardiovascular safety in large-scale clinical trials of saxagliptin (SAVOR, GENERATION, and Real World Evidence).
Keywords:saxagliptin, diabetes mellitus type 2, cardiovascular safety
Endocrinology: News, Opinions, Training. 2015; (4): 12–19.